Clinical Trials Logo

Clinical Trial Summary

Study DMX-IB 201 is a Phase 1/2a study of ibogaine consisting of an initial single ascending dose escalation stage to determine the maximum tolerated dose (MTD) or treat-to-target dose (TTD) in healthy volunteers, followed by a randomized, double-blind, placebo-controlled proof of concept stage to demonstrate the efficacy, safety and tolerability of the selected dose in opioid-dependent patients who seek medically supervised opioid withdrawal

Clinical Trial Description

Detailed description restricted as elements of this trial are part of a Phase 1 clinical trial. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05029401
Study type Interventional
Source DemeRx IB, Inc.
Contact M Luz
Phone +1 786 3473500
Email [email protected]
Status Recruiting
Phase Phase 1/Phase 2
Start date April 1, 2021
Completion date October 2023

See also
  Status Clinical Trial Phase
Withdrawn NCT03975192 - Neurostimulation for Opiate Withdrawal in the PICU N/A
Completed NCT03521960 - Buspirone for Opioid Tapering Phase 1
Enrolling by invitation NCT03012373 - Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts N/A
Completed NCT01945736 - Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal
Not yet recruiting NCT03397212 - Treatment of Withdrawal Symptoms With NADA Acupuncture in Chronic Pain Patients Phase 4
Completed NCT03971097 - The Effect of Self-Forgiveness on Self-Stigma in Addiction. N/A
Completed NCT03077932 - An App to Aid in Transitioning Off Opioid Medication N/A